Table 3.
Elastin-like polypeptides.
| Biomimetic peptide | Biomimetic sequence | Bioactive conjugate | Application | References |
|---|---|---|---|---|
| Elastin-like polypeptide (ELP) with Cys substitution | (VPGXG)n where X = Cys, Ala, or Val n = 6, 10, or 16 |
FITC-BSA | Sustained release of BSA as model (hydrogel) | Asai et al., 2012 |
| Cell-binding-ELP | TVYAVTGRGDSPASSAA [(VPGIG)2VPGKG(VPGIG)2]3VP | RGD sequence | Study of cell–matrix interactions (hydrogel) | Wang et al., 2014 |
| ELP conjugated to glucagon-like peptide 1 (GLP-1) | (GAGVPGGGVP)60GY and (GVGVP)120GWP | Glucagon-like peptide 1 (GLP-1) | Sustained release of GLP-1 to control blood glucose Peptide-peptide conjugate/self-assembled aggregates |
Amiram et al., 2013 |
| ELP conjugated to curcumin | MSKGPG[VPGXG]L = 60, 80, 160 WPC with X = V/I/E [1:3:1] | Curcumin carbamate | Anti-inflammation | Sinclair et al., 2013 |
| ELP conjugated to IFN-α | (VPGXG)90 X = A/G/V [2:3:5] |
IFN-α | Enhanced pharmacokinetics, tumor accumulation, and antitumor efficacy | Hu et al., 2015 |
| ELP conjugated to anti-FTL3 | G(VPGAG)192Y | Anti-FTL3 | Extended pharmacokinetic half-life for myeloid leukemia treatment (nanoparticles) | Park et al., 2020 |
| ELP conjugated to anti-CD99 | G(VPGAG)192Y | Anti-CD99 | Extended pharmacokinetic half-life for myeloid leukemia treatment (nanoworms) | Vaikari et al., 2020 |
| ELP conjugated to DR5 agonist (DRA) | (VPGVG)120 | DRA | Tumor growth inhibition (insoluble coacervate) | Manzari et al., 2019 |
| ELP conjugated to FGF-21 | (VPGXG)120 X = V/A/ [4:1] |
FGF-21 | Sustained anti-diabetic action (insoluble coacervate) | Gilroy et al., 2018 |
| ELP conjugated to vRGAE | V40C2, where V = VPGVG and C = VPGVGVPGVGVPGCGVPGVGVPGVG | vRGAE | Diabatic wound treatment (insoluble coacervate) | Kang et al., 2021 |